AzTrials
AzTrials

Thyroid Eye Disease, TEDNCT07056114

Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment

An observational study of Thyroid Eye Disease, TED, run by Tianjin Eye Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the assessment of extraocular muscles fibrosis in the thyroid eye disease. Read more about this study

Who is it for?
Ages 20 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Thyroid Eye Disease, TED
What is being tested?
The patients with active or inactive TED
How many people
58 participants
Where
1 siteChina
Study dates
1 Jan 2020to 1 Jun 2025
How long will I take part?
4 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Study Design and Participants Consecutive patients (n=40) with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score (CAS). The sex-matched control group (n=18) comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI. All participants underwent a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, Hertel exophthalmometry and intraocular pressure. A blood sample was obtained on the day of MR scanning to measure hematocrit.

Who may be able to join

  • Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024.

Who cannot join

  • Participants who reported any of the following were excluded: (1) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy and optic nerve disorders); (2) patients with dysthyroid optic neuropathy (DON).

Trial locations and contacts

1 site in 1 country.

China1 site
  • Tianjin Eye Hospital

    Tianjin

Other trials in China

About this study

Official title: Comprehensive Evaluation of Extraocular Muscle Fibrosis in Thyroid Eye Disease With Multi-modal Medical Images

The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the assessment of extraocular muscles fibrosis in the thyroid eye disease.

Read the detailed description

Thyroid eye disease (TED) is an autoimmune orbitopathy characterized by inflammation and remodeling of the orbital tissues. These changes can lead to the development of symptoms such as proptosis, diplopia, and cosmetically disturbing. Strabismic diplopia in the active phase TED results from restriction of muscle movement due to inflammatory and oedema of extraocular muscles (EOMs). Recent studies have demonstrated that patients with active TED receiving teprotumumab experienced a meaningful improvement in proptosis and strabismic diplopia. However, there are still patients with strabismic diplopia who require strabismus surgery in the inactive phase TED. Unfortunately, the dose-response relationship in strabismus surgery for TED still exhibits significant variability, potentially leading to unsatisfactory postoperative alignment.

EOMs are manipulated mechanically during surgery for strabismus. In the progression of TED, the heterogeneity in the biomechanical properties of the EOMs caused by fibrosis may contribute to the unpredictability of strabismic diplopia. Thus, evaluating their biomechanical property changes has the potential to provide invaluable information that improves our understanding of the pathogenic mechanisms of TED-related strabismus. Real-time tissue elastography (RTE) is a noninvasive modality that provides information on periocular and ocular tissues elasticity. It could also account for strain distribution inhomogeneity across large tissue areas, potentially serving as a powerful tool for detecting and monitoring pathological processes affecting EOM stiffness.

Biomechanical property changes are often based on corresponding changes in the morphology. Orbital magnetic resonance imaging (MRI) could help to quantitatively assess the clinical activity, fibrosis and other pathological changes of TED. Studies recently reported that native T1 mapping values provide the best discrimination of morphological and fibrotic information of EOMs, and the extracellular volume (ECV) fraction is a reliable tool to quantify EOMs fibrosis. Nevertheless, the correlation of this method to relevant muscle elasticity architectures remains unavailable.

Methods Study Design and Participants Consecutive patients (n=40) with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score (CAS). The sex-matched control group (n=18) comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI. All participants underwent a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, Hertel exophthalmometry and intraocular pressure. A blood sample was obtained on the day of MR scanning to measure hematocrit. Participants who reported any of the following were excluded: (1) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy and optic nerve disorders); (2) patients with dysthyroid optic neuropathy (DON). Our institutional ethics committee approved all study protocols, and patients provided written informed consent.

MR image acquisition and image analysis All participants were examined using a 3.0-T MR scanner (Siemens Magnetom Verio dot, Siemens Healthcare) and a 64-channel brain coil. On the basis of a previous report, the scan sequences included routine sequences (T1-weighted sequence, T2-weighted sequence, fat-suppressed, STIR sequence) and pre/postcontrast T1 mapping using a dual-flip-angle method. Postcontrast T1 mapping was repeated in identical prescription as precontrast T1 mapping 15 min after contrast injection. The extra-cellular volume (ECV) was calculated following the previously described methodology. The region of interest (ROI) was drawn at the thickest part of the muscle and its adjacent upper and lower levels in selected axial planes, and then MRI parameters of the medial rectus (MR) and lateral rectus (LR) muscles were measured from both sides. Two independent radiologists (L.X. and J.M.) delineated ROIs on the EOMs of all participants. Three repeated measurements were performed for each muscle slice, and the mean value was used for analysis. Radiologist L.X. repeated all evaluations twice at one-month intervals to assess intraobserver reliability.

Measurement of extraocular muscles stiffness The elasticity of the extraocular muscles was assessed using an ultrasound scanner equipped with real-time tissue elastography (EUB-7500; Hitachi Medical Systems, Tokyo, Japan). The images were acquired and analyzed following the previously described methodology. The system displays real-time color-coded elastography images overlaid on B-mode ultrasound. As this provides only qualitative stiffness assessment, we used the elastic ratio method for quantitative analysis. ROI was simultaneously placed on extraocular muscles and orbital fat, and the ROI was set as large as possible (3 × 3 mm). Orbital fat elasticity was used as an internal control. Subsequently, the elastic ratio was calculated by dividing the value obtained from the extraocular muscles by that of the orbital fat. A higher elastic ratio indicates greater stiffness in the extraocular muscles, which correlates with more advanced stages of fibrosis. Two investigators performed the extraocular muscles evaluation with real-time tissue elastography. We evaluated the images only when the pressure stabilized within the optimal 5-7 bar range.

Statistical analysis Statistical analyses were conducted using SPSS version 23 (IBM, Chicago, Illinois). Continuous variables are presented as mean ± standard deviation (SD), while categorical variables are reported as frequencies and percentages. Baseline characteristics, native T1 values, and elastic ratios were compared using analysis of variance (ANOVA) for continuous variables or chi-square tests for categorical variables, as appropriate. Our study selected the medial and lateral rectus muscles for data analysis, because of their ease in sonoelastographic imaging. The association between native T1 and elastic ratio was assessed using Pearson correlation analysis. Intraobserver agreement of MR parameters and elastic ratio were assessed using Bland-Altman methods and intraclass correlation coefficients. Receiver-operating characteristic (ROC) curves were built to determine the best threshold for quantitative elastic ratio to detect extraocular muscle fibrosis. ECV cutoff value of 48% was used as standard reference to determine the best threshold for elastic ratio value to detect extraocular muscle fibrosis in inactive TED. The optimal cutoff point was identified using the Youden index. All statistical tests were two-tailed, and a P value of <0.05 was considered statistically significant.

Being tested
The patients with active or inactive TED
Keywords
Thyroid eye disease, Real-time tissue elastography
Medical subject headings
Graves Ophthalmopathy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • The patients with active or inactive TEDOther

    The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score

Study groups in NCT07056114
Study groupRoleWhat they receive
patients groupConsecutive patients with moderate-to-severe TED
Receives: Other: The patients with active or inactive TED
control groupThe sex-matched control group comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MRI parameters (native T1 value and ECV) and elasticity of EOMs in the TED.

    Measured: Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jul 2025
  2. Study start1 Jan 2020
  3. Primary completion1 Jun 2025
  4. Study completion1 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
58 participants (actual)
Target duration
4 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07056114
Sponsor's protocol ID
No.21JCYBJC01660
Status last verified
Jun 2025
First submitted
28 Jun 2025
Last updated
9 Jul 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Thyroid Eye Disease, TED, run by Tianjin Eye Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MRI parameters (native T1 value and ECV) and elasticity of EOMs in the TED. (time frame: Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in